more

Veracyte (VCYT)

(Delayed Data from NSDQ)

$20.63 USD

+0.51 (2.53%)

Updated May 9, 2024 04:00 PM ET

After-Market: $20.62 -0.01 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum B VGM

Industry Rank:

Top 37% (92 out of 250)

Industry: Medical - Instruments

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Veracyte (VCYT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research Published on March 14,2019

Veracyte (VCYT) delivered earnings and revenue surprises of 38.46% and 5.82%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

VCYTPositive Net Change

Zacks.com featured highlights include: Radiant, Great Lakes, Clarus, Veracyte and First BanCorp

by Zacks Equity Research Published on March 05,2019

Zacks.com featured highlights include: Radiant, Great Lakes, Clarus, Veracyte and First BanCorp

construction

5 Stocks With Recent Price Strength to Maximize Your Gains

by Zacks Equity Research Published on March 04,2019

Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Will Veracyte (VCYT) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research Published on February 18,2019

Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

VCYTPositive Net Change

Veracyte (VCYT) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research Published on October 29,2018

Veracyte (VCYT) delivered earnings and revenue surprises of 50.00% and 9.06%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

VCYTPositive Net Change

Veracyte (VCYT) Q3 Earnings Preview: Here's What to Look Out For

by Zacks Equity Research Published on October 22,2018

Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.